Actively Recruiting
Observational Study of Ruxolitinib Jakavi in Patients with Acute and Chronic Graft-Versus-Host Disease
Led by Novartis Pharmaceuticals · Updated on 2026-06-08
395
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety and effectiveness of Jakavi4 ruxolitinib in patients who have acute or chronic graft-versus-host disease GVHD during routine clinical practice. This observational study is sponsored by Novartis Pharmaceuticals and focuses on understanding how ruxolitinib works in real-world settings to help patients with GVHD. Patients with acute and chronic GVHD who are treated with ruxolitinib are followed as part of this study. There is one study group consisting of patients receiving ruxolitinib. The study monitors patients over time to gather data on infections, deaths related to infection, and other health events up to one year after treatment. Participants will have their health closely monitored throughout the study period, including the number and severity of infections, response to treatment for GVHD, survival, and bone-related events. Data on overall response rates for acute and chronic GVHD, timing of responses, and duration of effects will also be collected. The study lasts up to one year for each participant, during which researchers review medical records and outcomes related to their GVHD and treatment with ruxolitinib.
CONDITIONS
Brief Title
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
